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Reduced crystallization inhibition by urine from women with [2]. Current treatments aim to reduce supersaturations,
nephrolithiasis. and are generally successful [3–10]. Our findings in males
Background. Human urine is known to inhibit growth, ag- [1] suggested that we might broaden both our diagnosticgregation, nucleation, and cell adhesion of calcium oxalate
and therapeutic range through efforts to measure inhibi-monohydrate (COM) crystals, the main solid phase of human
tions in practice and find medications that improve urinekidney stones. This study tested the hypothesis that low levels
of inhibition are present in women with calcium oxalate stones inhibition.
and, therefore, could promote stone production. A major weakness of our prior study was its exclusion
Methods. In 17 stone-forming women and 17 normal women of women. Given the vast differences between the sexesmatched in age within five years, inhibition by dialyzed urine
with respect to stone disease [11–13], women may wellproteins of COM growth and aggregation was examined, as
have different patterns of inhibition defects, or none atwell as whole urine upper limits of metastability (ULM) for
COM and calcium phosphate (CaP) in relation to the corre- all. We present here a formal, controlled study of inhibi-
sponding supersaturation (SS). tion among women who form calcium oxalate stones, and
Results. Compared to normals, patient urine showed a re- matched normal women. Among men, in addition to crys-duced ULM in relation to SS. In contrast to men, there was
tal growth and nucleation, inhibition of crystal aggrega-no difference in growth inhibition.
tion and adherence of crystals to cultured renal cellsConclusions. Reduced CaP and CaOx ULM values in rela-
tion to SS are a characteristic of female stone formers. This were measured. The last of these proved without discrim-
defect could promote stones by facilitating crystal nucleation. ination, and we omit it here. Aggregation inhibition was
Abnormal inhibition may well be a very important cause of virtually without significance, as well, but was re-testedhuman nephrolithiasis.
in this study, as others have reported differences between
normals and patients in studies using either isolated urine
proteins [14] or different methods to measure aggrega-Elsewhere we have presented evidence that urine from
tion [15].male calcium oxalate (CaOx) stone formers is less able
than urine from matched normal subjects to slow the
growth of calcium oxalate crystals, and raise the supersat- METHODS
uration needed for nucleation [1]. This evidence supports Patients and controls
the idea that inhibition of crystallization is an important
Seventeen women were randomly selected if they haddefense against stones and that deficiencies in that de-
at least one or two separate new stone episodes andfense may well be a clinical factor in stone disease. Patho-
whose stones proved to be principally CaOx; exclusiongenesis of calcium renal stones has for many years been
criteria included those whose stones had ever containeddescribed in terms of diseases and inherited traits that
uric acid, cystine, or struvite. The number of stones perincrease urine supersaturation (SS) with respect to the
patient ranged from a low of 2 to a high of 76. The timecommon stone-forming salts, calcium oxalate (CaOx),
from first stone to entering our program ranged from 2calcium phosphate (CaP), uric acid, cystine, and struvite
months to 23 years. So wide a spread is usual in samples
of calcium stone formers. No patient had stones from a
systemic disease, including primary hyperparathyroid-Key words: calcium oxalate, upper limit of metastability, crystal growth,
renal stones, kidney stones, stone disease. ism, sarcoidosis, vitamin D excess, bowel disease of any
kind, renal tubular acidosis, or primary hyperoxaluria.Received for publication July 25, 2001
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above 1.25 mg/dL, and none had hereditary or acquired A 100 mL aliquot of the urine collected for this re-
search was dialyzed using a 3500 Dalton membrane atanatomical disorders of the kidney or the urinary drain-
age system. For patients on medications that could affect 4C for 48 hours against 10 mmol/L NaCl, 5 mmol/L
Tris, pH 7.2, with two changes of the bath. The proteinstones or mineral metabolism, medications were discon-
tinued one week before the 24-hour urines were ob- concentration was measured by the ninhydrin method
[18]. If the urine proteins were too dilute to be used intained. The diet was not altered from what was in effect
at the time of this study. Our program specifically avoids the assays, the sample was concentrated and the protein
concentration remeasured. This protein mix was usedlow-calcium diets, and therefore, no patient was know-
ingly placed on such a diet. Each patient was matched for the assays of growth and aggregation inhibition.
Upper limits of metastability. A modification of thewith a normal subject within five years of age. Normals
had no dipstick proteinuria above trace, no family history method described by Nicar, Hill, and Pak was used to
determine the ULM of CaOx and brushite in humanof stones, no systemic or renal disease ever diagnosed,
and were taking no medications that either would suggest urine as previously described by our laboratory [1, 18–
20]. An aliquot of urine from a 24-hour collection wassystemic or renal disease or that could influence mineral
metabolism. For the one patient of African American centrifuged for 30 minutes at 3000 r.p.m. to remove de-
bris. Urine pH was adjusted to 6.4 by the addition of HClorigin, we found a race-matched normal. All other pa-
tients were European Caucasians. or NaOH as required. A urine pH of 6.4 was required, as
the addition of calcium to urine at a lower pH mightPrior to this research, each patient was studied for
clinical purposes using three 24-hour urine measure- precipitate either CaOx or CaP and thus give an unclear
endpoint for the assay. Ten milliliters of each urine sam-ments, each with a corresponding blood sample drawn
between 7 and 9 am in the post-absorptive state. From ple were placed into each of 13 tubes, and sodium azide
was added to each tube at a final concentration of 0.02%this inquiry and using the following criteria, metabolic
abnormalities were as follows: urine calcium above to prevent bacterial growth. The tubes were placed in a
water bath at 37C and magnetically stirred. To initiate140 mg/g creatinine [16], N  9; urine citrate below 500
mg/day, N  7; urine oxalate above 45 mg/day, N  3; CaOx precipitation, increasing amounts of sodium oxa-
late were added to each set of tubes. One tube had nourine uric acid above 750 mg/day, N  2. Seven patients
had only one abnormality (3 calcium, 4 citrate); eight oxalate to serve as a blank. The pH of each tube was
checked hourly during the incubation, and 1 mol/L HClpatients had two abnormalities (calcium and oxalate 2;
calcium and citrate, 2; calcium and uric acid, 2, citrate or 1 mol/L NaOH was added as required to maintain
the pH at 6.4. The total volume of additions was alwaysand oxalate, 2); two patients had no abnormalities.
below 1% of the total volume of urine in each tube.
Laboratory studies After three hours, the samples were checked for visible
precipitation; the tube with the lowest amount of oxalateConventional studies and preparation of dialyzed urine
proteins. For each patient and normal, a 24-hour urine added that initiated crystallization was considered the
endpoint. The SS at the point of precipitation was calcu-was obtained for the measurement of established stone
risk factors: calcium, oxalate, citrate, phosphate, pH, lated using EQUIL2, assuming all chemical concentra-
tions were unchanged except for oxalate, which wasmagnesium, and uric acid. To calculate SS, sulfate, am-
monium ion, chloride, potassium, and sodium were mea- taken as the initial measured oxalate concentration plus
the amount added to the tube. ULM for CaP was deter-sured also. Urine creatinine was measured to assess the
completeness of collection. SS for CaOx and CaP was mined in the same fashion, except calcium chloride was
added to the urine samples to precipitate CaP, which iscalculated using the EQUIL 2 [17]. Supersaturation is
calculated as the ratio of the activity product to the known to be in the form of brushite under these condi-
tions [20].solubility product. Values greater than one indicated
that the solution was supersaturated, less than one the CaOx crystal growth inhibition. Calcium oxalate mon-
ohydrate (COM) crystal seed slurries (0.8 mg/mL) weresolution was undersaturated, and a value of one was a
state of saturation where there was equilibrium between prepared by the addition of 8 mg of COM crystal (aver-
age diameter 2 to 5 m) to 10 mL of 90 mmol/L NaCl,the solid and liquid phase of a salt. Each patient also
was evaluated clinically prior to entering this research 10 mmol/L Tris buffer, pH 7.2. The slurry was mixed
with a magnetic stirrer overnight at 1100 r.p.m. The seedprotocol using three 24-hour urine measures, each with
a corresponding serum sample, as we have described slurry was added to 2 mL of a metastable CaOx solu-
tion, consisting of 0.5 mmol/L Ca, 0.5 mmol/L oxalate,elsewhere [11]. These results, not reported here, were
used in conjunction with medical history, stone analyses, 90 mmol/L NaCl, 10 mmol/L Tris, pH 7.2, contained in
a quartz cuvette, 37C, and magnetically stirred at 1100and all prior radiographs relevant to stones to ascertain
clinical classification, as noted earlier in this article, and r.p.m. Oxalate consumption was initiated by the addition
of seed crystals and was monitored for 400 seconds withto guide treatment.
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a continuous-recording spectrophotometer at 214 nm. tical calculations were performed using Systat software
(Systat, Inc., Chicago, IL, USA).Data were collected using a Lambda 7 spectrophotome-
ter (Perkin Elmer Corp., Norwalk, CT, USA) interfaced
to a personal computer by a data-acquisition system (Lake-
RESULTS
shore Technologies, Chicago, IL, USA). The rate of oxa-
Of the 12 conventional measurements used to assesslate consumption follows second-order kinetics, and the
stone forming risk (Fig. 1), and including urine creatininevelocity of the reaction was derived from the integrated
(not shown), none differed by t test between normalsrate equation [21]. The assay was run with and without
and patients except urine calcium excretion (238 vs.the urine proteins in an alternating fashion such that each
137 mg/24 hr, patients vs. normals, P  0.02), even whenurine sample was sandwiched by control measurements.
we relaxed the correction for multiple significance test-Results for the protein samples are expressed as a per-
ing. The boxes of Figure 1 narrow to a waist at the me-centage of the reaction velocity of the controls, such that
dian value, and their notched areas enclose the 95% non-greater inhibition will result in smaller reaction velocities
parametric confidence limits, which overlap, indicating aand a lower percentage of control. Urine protein was
lack of significant difference for all tests. In contrast toadded to the assay at the fixed amount of 32 g and
t tests, the non-parametric notch boxes do not supportduplicates were run at this protein concentration.
higher urine calcium among patients [23]. The lack ofCaOx crystal aggregation. COM crystal slurries 0.8
distinctive hypocitraturia among female patients versusmg/mL (average crystal diameter of 2 to 5 m) were pre-
normal women is not as we have shown in the past [11].pared in 10 mmol/L acetate, pH 5.7, were equilibrated
In addition to excretion rates, concentrations of calcium,overnight at 37C, and were magnetically stirred at 1100
oxalate, phosphorus and citrate also did not differ be-r.p.m. The crystals and solution come to equilibrium so
tween patients and normals (not shown). Overall, andthat crystals no longer dissolve or grow. The slurry was
only by t test, hypercalciuria was the only distinctive traitthen pipetted into multiple tubes, each used for a single
of these stone forming women.assay. Urine protein samples were added to the stirred
Among normals SS and ULM (Fig. 2) were correlatedslurries 30 minutes prior to the assay. A 2 mL aliquot of
for CaOx (Fig. 2B) and CaP (Fig. 2A) as we have shownthe crystal slurry was then transferred to a quartz cuvette
in the past for men [1], men and women in a protocolmaintained at 37C and was constantly monitored at 620
without gender- and age-matched controls [24], andnm. In this system, OD620 is proportional to the mass of
among hypercalciuric rats [18] (r  0.83, and 0.497, P crystal per unit volume [22]. The slurry was initially
0.0001 and 0.043, CaOx and CaP, respectively). By con-stirred at 1100 r.p.m. to obtain a stable baseline, and
trast, CaOx SS and ULM were not correlated amongthen crystal aggregation was induced by slow stirring at
patients (r  0.347, P  0.172) but CaP SS and ULM500 r.p.m. for 170 seconds. Stirring was stopped, and
were correlated (r  0.575, P  0.016). Mean values forparticle sedimentation was monitored. The rate of fall
SS differed between normals and patients (6.1 vs. 8.5in OD620, measured as the slope of the straight portion of
and 1.04 vs. 1.89, for SS CaOx and SS CaP, normal vs.the plot of OD versus time, reflected the average particle
patient, P  0.02 and 0.05, respectively). These highersize and was taken as a measure of aggregation [22]. The
SS values seem to reflect the relative hypercalciuria ofassay was run with and without the urine proteins in
stone formers vs. normals. ULM values did not differan alternating fashion such that each urine sample was
(4.0 vs. 3.4, and 21 vs. 21, for ULM CaP and CaOx,sandwiched by control measurements. The results for
normals vs. patients, respectively; all P values  NS).the protein samples are expressed as a percent of the
By contrast, when the difference of ULM CaP betweensedimentation rate of the controls. Urine protein was
normals and patients was tested using ANOVA with SSadded to the assay at 0.006% of the 24-hour urine protein
CaP as covariate, the P value fell from 0.18 by t test toexcretion and duplicates were run at each protein level.
0.01 (F for regression of ULM on SS 13.1, P  0.001,
Analysis adjusted least square means 4.265 vs. 3.204, normal vs
patients, respectively; slopes were not different, P Routine t tests and nonparametric estimates were used
0.15 for cross term). For CaOx, such analysis made noto test differences between patients and normals. Be-
difference (P values were 0.87 and 0.31, t tests andcause ULM varied with SS, differences between normals
ANOVA, respectively). Altogether, patients were moreand patients were tested by analysis of covariance. The
supersaturated, and ULM correlated enough with super-homogeneity of slopes was tested using the P value for
saturation, so that when SS was considered, CaP ULMthe interaction term of group by SS. When slopes were
values were lower in patients. This is a way of sayingheterogeneous, the interaction term was removed from
that CaP ULM was reduced among patients in relationthe final model. In some bivariate displays, 68% confi-
to SS. The visual experience of this relative lowering candence ellipses were used to outline the principle concen-
trations of points from patients versus normals. All statis- be seen by the droop of patient points down toward the
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Fig. 1. Notched box plots of standard urine stone risk factors. All values are 24-hour urine in mg except for phosphorous and uric acid (g/day),
volume (liters), and sodium, potassium, sulfate and ammonium ion (mEq). Abbreviations are: FN, female normals; FSF, female stone formers.
Stone formers and normals did not differ in regard to any measurement by t test except calcium excretion. Notches of bars represent 95% confidence
limits, which overlap between FN and FSF in all cases.
Fig. 2. Upper limits of metastability (ULM) and supersaturation (SS) values. Values of ULM versus SS for (A) CaP and (B) CaOx are for normals
() and patients () are all above the diagonal lines of identity with two exceptions. ULM correlates with SS for CaP and CaOx for normals,
and CaP for patients. Ellipses are calculated at 1SD to contain 68.8% of points.
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We do not know what controls ULM, but among all
of the excretion rates (Fig. 1) and concentrations (not
illustrated) in urine, ULM CaP correlated best with urine
citrate molarity (r  0.66, P  0.001) using standard
multivariate linear modeling. For normals (Fig. 4A), r 
0.754, P  0.001; for patients, values were 0.667, and
P 0.003. Slopes did not differ using multivariate analy-
sis. ULM CaOx and urine citrate molarity correlated
(r  0.64, P  0.005) for patients (Fig. 4B), but not for
normals (r  0.23, P  0.37). Slopes of ULM CaOx
versus citrate molarity for normals and patients were
not homogeneous by multivariate linear modeling (P 
0.05), as expected from the discordance seen in the figure.
In other words, urine citrate molarity is an important
correlate of the ULM for CaP in patients and normals,
and for ULM CaOx in patients. As such, citrate may be
a true molecular determinate of ULM and therefore in
that way defend against stone formation.
Despite the dominant influence of urine citrate con-
centration on ULM (Fig. 4), ULM for CaP and CaOx
of patients and normals did not differ when citrate con-
Fig. 3. ULM  SS distances. Normals () cluster in an 80% ellipse centration was used as a covariate. This is illustrated by
of containment that includes only 4 patient points (). Six patient points the overlap of points (Fig. 4, A and B), and by the ad-are 2 SD below the normal mean for CaOx ULM to SS distance (vertical
justed means and P values for the analysis of covariancedashed line) and 5 are 2 SD below the normal mean for CaP ULM to
SS distance (horizontal dashed line). Border plots demonstrate the low (3.56 vs. 3.91 and 21.1 vs. 20.1, normal versus patient,
values of the distance for patients, especially in relation to CaP (right CaP and CaOx ULM, respectively; P  NS, both com-border).
parisons). Because patient and normal values for citrate
concentration overlap greatly, the effects of citrate, though
powerful, do not explain differences in the ULM or the
diagonal line of identity on the Figure 2A; 10 solid points ULM to SS distance between patients and normals.
(patients) are closer to the line of identity than all but A final, and perhaps more obvious way to display
one normal point for CaP (Fig. 2A). By contrast, 6 are the impressive ULM to SS distance difference between
close to the line of identity for CaOx (Fig. 2B), the patients and normals is simple quantile plotting of all
greater spread of data accounting for the lack of statisti- points (Fig. 5, A and B). The great population separa-
cal significance for low ULM. tion of patients from normal for CaP (Fig. 5A) left 10 pa-
Another way of showing this critical difference in the tients below the 1.5 SD distance from the normal mean,
relationship of ULM to SS between patients and normals wherein only one normal value fell; the separation of
is to calculate the difference between ULM and SS. values is also shown by the small inset notched box plot.
When the difference between ULM and SS for CaP is For CaOx, the population of patients appears split into
plotted against the corresponding difference for CaOx two utterly different groups, one of them normal and
(Fig. 3), the normal values cluster in a small space. All the other very much below. As a result, the populations
but 2 of the 17 normal points lie within an 80% confi- overlap in their notched bars, despite a sizable abnormal
dence ellipse that contains only 4 patient points. Patient subgroup. One must say ULM to SS distance is a seem-
points spread out over much of the graph. Six lie 2 SD ingly robust differentiator of patient from normal.
below the normal mean for the ULM  SS CaOx dis- CaOx crystal growth inhibition by patient and normal
tance (vertical line), and five 2SD below the correspond- urine proteins was quite the opposite; values (Fig. 5C)
ing line for CaP (horizontal line). What seems a fair for patients and normals overlapped. Mean values were
summary of the data is a generally marked scatter of not different (40.2 vs. 41.6% control growth, normal vs.
patient data, as if some force normally holding ULM patient, PNS). The same for aggregation (71 vs. 73.5%
and SS in a mutually coherent orbit was weak. Direct control, normal vs. patient, P  NS). The two groups of
comparisons of mean values for the ULM to SS distance points overlap with a single outlier that appeared to pro-
confirms the CaP abnormality as a group characteristic, mote aggregation. Unlike men, who exhibited a robust
and that for CaOx as a subset phenomenon (2.88 vs. growth disorder, women exhibited only a disorder of the
1.55, and 14.1 vs. 12.3, normal vs. patient, CaP and CaOx, ULM to SS distance. Like men, women stone formers
had no apparent abnormality of aggregation inhibition.respectively, P  0.003, and P  NS).
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Fig. 4. Effects of urine citrate on ULM values. (A) ULM CaP (y axis) rises with urine citrate concentration (x axis); values of the regression
coefficients are significant for both patients () and normals (). (B) ULM CaOx (y axis) rises with urine citrate concentration for patients but
not normals (regression coefficients are in the Results section). Ellipses are calculated at 1SD to contain 68.8% of points.
DISCUSSION reduced, but also chaotic. By this we mean that normal
women, and men [1] have values for the ULM to SSAs in many matters, women differ from men in their
distances for CaOx and CaP confined in a small two-approach to forming stones. Whereas men with stones
dimensional space (Fig. 3). Patients, by contrast, havelack proper inhibition of crystal growth, and inhibition
values spread all over the area of the graph, meaning aof both CaOx and CaP nucleation, women display only
looser relationship between ULM and SS.the latter two, the growth inhibitions of patients and
A low ULM to SS distance offers an easy metaphornormals being indistinguishable. Like our men stone-
for stone formation. As urine concentrates stone formingformers [1], women with stones were relatively hypercal-
salts through water extraction, to raise SS, normal kid-ciuric, but normal otherwise with respect to the common
neys contrive a linked defense of higher ULM, whereasurine stone risk factors such as oxalate and citrate excre-
stone former kidneys, being somehow less endowed, de-tions [11]. Also like men, women with stones had no
fend themselves less well. The lower ULM means a lowerdefect of urine crystal aggregation inhibition. It would
SS is needed to create crystal nuclei, or a high SS is moreappear, therefore, that defects of nucleation inhibition
able to do this, and stones form. Nicar, Hill and Pak of-are common to the two sexes, and the most general and
fered this idea many years ago [20]; our work amplyreliable mark of a stone former.
confirms theirs, and the two bodies of work suggest thatOne should not say, merely, that nucleation inhibition
much more needs be done to understand regulation ofis defective in being reduced compared to a given stan-
ULM, and potential defects of ULM regulation in stonedard. That is not the case. Rather, the supersaturation
formers.needed to induce crystallization is low in stone formers
One might rejoin by noting that the stones were cal-compared to the supersaturation of the urine itself. For
cium oxalate, yet the most robust disorder was in ULMreasons we do not understand, the ULM correlates with
to SS distance for CaP. In fact, the women patients assupersaturation, being higher in urines with a higher
a group had a low mean value for this distance, whereassupersaturation than in those with lower supersatura-
for CaOx the abnormality was within only a subgroup.tions [1, 18, 19]. Rats, men, women, and even panels of
We should answer that decades of work have linked CaPunselected stone formers display this curious phenome-
and CaOx crystallizations. The two crystals ably nucleatenon of linkage. Stone formers appear to lose this linkage,
each other [25, 26]. Randall’s plaques, long viewed asor perhaps they possess some weaker form of it, so we
find the distance between the ULM and SS is generally the tissue site precursor to clinical stones [27, 28] are in
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Fig. 5. Frequency distributions of four tests of inhibition. Values for patients () and normals () deviate greatly for the ULM to SS distance
for CaP (A). For the ULM to SS distance for CaOx (B) about half of patient points differ dramatically from normals, the others being indistinguishable.
(C ) Growth inhibition by patients and normals was indistinguishable, as was aggregation inhibitions (D). Lines show 1.5 and 2 SD displacements
from the normal means. Notched box plots are separate for CaP (A) and connote a highly significant population difference, but overlap for CaOx
(B) connoting a difference within subgroups.
fact composed of CaP [29]. At the heart of many CaOx brushite may be the nidus for calcium stone formation
[32]. Once formed, CaP would reduce the SS neededstones, one finds a remnant of CaP [30, 31], often called
the nucleus of the stone, though this is without proof. for CaOx to form, as an overgrowth on a CaP surface.
Therefore, a CaP defect may well promote CaOx stones.Pak, Eanes and Ruskin have shown that brushite sponta-
neously precipitates from urine as supersaturation is The molecules that create the relatively high ULM of
urine compared to simple buffers are not known [33].raised by addition of calcium and have proposed that
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In women, as men, citrate is well correlated with CaP no inhibitor abnormality in our past study [1]. The differ-
ence is surely due to our having three robust inhibitionULM, but not as well with CaOx ULM. However, be-
cause citrate molarities of patients and normals over- measurements for men, as growth inhibition defects were
very common. Since men are the predominant sex in stonelapped in men [1] and women, low citrate is not the
reason for what was found in our current study. The disease, a growth inhibition assay seems prudent to use,
many macromolecular inhibitors in urine [1, 34–36] could as well as ULM, in future characterization of patients.
each alter ULM, but little has been done to show their
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